Gregory M. Asnis, MD

Letter to the Editor

Lurasidone-Induced Urinary Retention

April 4, 2023

Gregory M. Asnis, MD, comments on a report recently published in the PCC.

Gregory M. Asnis

Original Research

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

March 15, 2013

Gregory M. Asnis, Anjana Bose, Carl P. Gommoll, et al

Original Research

Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment: A Randomized Controlled Trial

December 28, 2010

Maurizio Fava, Gregory M. Asnis, Ram K. Shrivastava, et al

Original Research

Effect of Lamotrigine on Cognitive Complaints in Patients With Bipolar I Disorder

November 1, 2004

Arifulla Khan, Lawrence D. Ginsberg, Gregory M. Asnis, et al

Letter to the Editor

Ribavirin May Be an Important Factor in IFN-Induced Neuropsychiatric Effects

April 1, 2004

Gregory M. Asnis, Andrew H. Miller, Charles L. Raison

Letter to the Editor

Combined Antidepressant Treatment: A Risk Factor for Switching in Bipolar Patients

April 1, 2002

Vilma Gabbay, Mary Alice O'Dowd, Gregory M. Asnis

Original Research

Zolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients

October 31, 1999

Gregory M. Asnis, Amal Chakraburtty, Eugene A. DuBoff, et al

Lurasidone-Induced Urinary Retention

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment: A Randomized Controlled Trial

Effect of Lamotrigine on Cognitive Complaints in Patients With Bipolar I Disorder

Ribavirin May Be an Important Factor in IFN-Induced Neuropsychiatric Effects

Combined Antidepressant Treatment: A Risk Factor for Switching in Bipolar Patients

Zolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients

ELSEWHERE:

FOLLOW US:

Gregory M. Asnis, MD

Lurasidone-Induced Urinary Retention

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment: A Randomized Controlled Trial

Effect of Lamotrigine on Cognitive Complaints in Patients With Bipolar I Disorder

Ribavirin May Be an Important Factor in IFN-Induced Neuropsychiatric Effects

Combined Antidepressant Treatment: A Risk Factor for Switching in Bipolar Patients

Zolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles